MYGNMyriad Genetics, Inc.

$454M

Q4 2019 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$195M-10.0% YoY

Gross Profit

$146M74.6% margin

Operating Income

-$9M-4.5% margin

Net Income

-$8M-4.3% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+4.7%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$5M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$501M

Stockholders' Equity

$1.1B

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$195M	$217M	-10.0%
Gross Profit	$146M	$165M	-11.7%
Operating Income	-$9M	$6M	-244.3%
Net Income	-$8M	$3M	-419.2%

Revenue Segments

Diagnostics

$178M91%

All Other Segments

$18M9%

Geographic Segments

UNITED STATES

$182M93%

Non Us

$13M7%

MYGN Q4 2019 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena